Thelansis

  Non-metastatic castration-resistant prostate cancer (nmCRPC), or M0 CRPC, is a transitional stage in which patients exhibit resistance to castration (testosterone levels drop below 50 ng/mL) after undergoing ADT. At this stage, no visible metastases appear on standard imaging exams, PSA levels continue to rise, reaching a minimum increase of 25% from their lowest point (starting with a PSA level of at least 1.0 ng/mL) and a minimum rise of 2 ng/mL, with confirmation required from a second measurement. PSA progression can happen before the detection of metastases, either due to local recurrence in the prostate bed after prostatectomy or persistent local disease following radical radiation therapy, or in cases where no disease is detected at the primary site, no involved lymph nodes are found in computed tomography (CT) or magnetic resonance imaging (MRI) (lymph nodes smaller than 1.5 cm in the pelvis are not considered). No disease is observed in bones or visceral organs. Most n...